Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile
Hummingbird Bioscience

@hummingbirdbio

Hummingbird Bioscience is a clinical stage biotech company focused on discovering and developing antibody-based biotherapeutics for the treatment of cancer.

ID: 3369056830

linkhttp://www.hummingbirdbioscience.com calendar_today10-07-2015 10:10:34

212 Tweet

207 Followers

155 Following

Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Ben Ayers, VP of Antibody-Drug Conjugates at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering & Therapeutics Asia. Antibody Engineering #adc #drugresistance #biotech

Ben Ayers, VP of Antibody-Drug Conjugates at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering &amp; Therapeutics Asia. <a href="/AntibodyEngIC/">Antibody Engineering</a> #adc #drugresistance #biotech
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Angèle Maki, Chief Business Officer of Hummingbird Bioscience, will be attending BIO-Europe in Stockholm, Sweden. To learn more about our validated epitope-focused antibody discovery platform capabilities, please reach out to connect with Angèle. #antibodydiscovery

Angèle Maki, Chief Business Officer of Hummingbird Bioscience, will be attending BIO-Europe in Stockholm, Sweden. To learn more about our validated epitope-focused antibody discovery platform capabilities, please reach out to connect with Angèle. 
#antibodydiscovery
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Press release: bit.ly/3NvYRP5 Hummingbird Bioscience will present a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium. #antibodydrugconjugates

Press release: bit.ly/3NvYRP5

Hummingbird Bioscience will present a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium.

#antibodydrugconjugates
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

The Hummingbird Bioscience team had a ball of a time at SuperBowl Mount Faber last month. The team united around the mission of leaving no pin standing, and had a great time bonding before the Deepavali festivities started.

The Hummingbird Bioscience team had a ball of a time at SuperBowl Mount Faber last month. The team united around the mission of leaving no pin standing, and had a great time bonding before the Deepavali festivities started.
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Jerome Boyd-Kirkup, Chief Scientific Officer at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering & Therapeutics San Diego. Read more in the interview: bit.ly/41lJYqF Antibody Engineering #adc #drugresistance #biotech

Jerome Boyd-Kirkup, Chief Scientific Officer at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering &amp; Therapeutics San Diego. Read more in the interview: bit.ly/41lJYqF 
<a href="/AntibodyEngIC/">Antibody Engineering</a> #adc #drugresistance #biotech
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Press release: bit.ly/3PqPdyc Hummingbird Bioscience has granted Immunome, Inc. an exclusive, worldwide license to novel monoclonal antibodies that are directed to a single undisclosed target. #biotech #licensing #outlicensing #ADC

Press release: bit.ly/3PqPdyc

Hummingbird Bioscience has granted <a href="/Immunome/">Immunome, Inc.</a> an exclusive, worldwide license to novel monoclonal antibodies that are directed to a single undisclosed target. #biotech #licensing #outlicensing #ADC
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Hummingbird Bioscience will be sharing Trial-in-Progress posters for HMBD-001 trials NCT05919537 and NCT05910827 at #AustralianPrecisionOncologySymposium2025 #APOS25 #PrecisionOncology Omico Australia

Hummingbird Bioscience will be sharing Trial-in-Progress posters for HMBD-001 trials NCT05919537 and NCT05910827 at #AustralianPrecisionOncologySymposium2025 #APOS25 #PrecisionOncology <a href="/OmicoAustralia/">Omico Australia</a>
Hummingbird Bioscience (@hummingbirdbio) 's Twitter Profile Photo

Our Chief Executive Officer Piers Ingram is attending BioCentury East-West #Biopharma Summit to discuss the upcoming innovations in Asia’s biopharma landscape. We look forward to meeting the community and catching up! Asia CEO Roundtable 5 March 2025 11:15AM-12:30PM SGT

Our Chief Executive Officer Piers Ingram is attending <a href="/BioCentury/">BioCentury</a> East-West #Biopharma Summit to discuss the upcoming innovations in Asia’s biopharma landscape. We look forward to meeting the community and catching up! 
Asia CEO Roundtable
5 March 2025
11:15AM-12:30PM SGT